Rapid Micro Biosystems Inc (RPID)

$0.8474

+0.02

(+2.1%)

Market is closed - opens 7 PM, 22 May 2024

Insights on Rapid Micro Biosystems Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 6.33M → 5.61M (in $), with an average decrease of 11.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -11.17M → -13.32M (in $), with an average decrease of 19.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.0% return, outperforming this stock by 57.9%

Performance

  • $0.83
    $0.87
    $0.85
    downward going graph

    2.94%

    Downside

    Day's Volatility :5.17%

    Upside

    2.3%

    downward going graph
  • $0.74
    $1.19
    $0.85
    downward going graph

    12.94%

    Downside

    52 Weeks Volatility :37.82%

    Upside

    28.57%

    downward going graph

Returns

PeriodRapid Micro Biosystems IncSector (Health Care)Index (Russel 2000)
3 Months
-10.8%
-0.6%
0.0%
6 Months
-17.73%
12.1%
0.0%
1 Year
-16.92%
11.3%
0.0%
3 Years
-96.04%
17.6%
-20.1%

Highlights

Market Capitalization
35.6M
Book Value
$2.48
Earnings Per Share (EPS)
-1.21
PEG Ratio
0.0
Wall Street Target Price
4.75
Profit Margin
-224.73%
Operating Margin TTM
-254.38%
Return On Assets TTM
-23.24%
Return On Equity TTM
-40.17%
Revenue TTM
23.1M
Revenue Per Share TTM
0.54
Quarterly Revenue Growth YOY
11.4%
Gross Profit TTM
-8.5M
EBITDA
-53.1M
Diluted Eps TTM
-1.21
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.27
EPS Estimate Next Year
-1.14
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Rapid Micro Biosystems Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 460.54%

Current $0.85
Target $4.75

Company Financials

FY19Y/Y Change
Revenue
16.5M
↑ 50.56%
Net Income
-21.2M
-
Net Profit Margin
-128.22%
-
FY20Y/Y Change
Revenue
16.1M
↓ 2.63%
Net Income
-37.1M
↑ 75.14%
Net Profit Margin
-230.63%
↓ 102.41%
FY21Y/Y Change
Revenue
23.2M
↑ 44.5%
Net Income
-73.5M
↑ 98.3%
Net Profit Margin
-316.48%
↓ 85.85%
FY22Y/Y Change
Revenue
17.1M
↓ 26.25%
Net Income
-60.8M
↓ 17.3%
Net Profit Margin
-354.91%
↓ 38.43%
FY23Y/Y Change
Revenue
22.5M
↑ 31.44%
Net Income
-52.5M
↓ 13.71%
Net Profit Margin
-232.99%
↑ 121.92%
Q1 FY23Q/Q Change
Revenue
4.4M
↓ 7.7%
Net Income
-16.4M
↑ 0.66%
Net Profit Margin
-376.02%
↓ 31.24%
Q2 FY23Q/Q Change
Revenue
5.0M
↑ 15.11%
Net Income
-13.9M
↓ 15.57%
Net Profit Margin
-275.81%
↑ 100.21%
Q3 FY23Q/Q Change
Revenue
5.0M
↓ 0.66%
Net Income
-14.0M
↑ 0.93%
Net Profit Margin
-280.21%
↓ 4.4%
Q4 FY23Q/Q Change
Revenue
6.1M
↑ 22.85%
Net Income
-13.4M
↓ 4.45%
Net Profit Margin
-217.93%
↑ 62.28%
Q1 FY24Q/Q Change
Revenue
6.3M
↑ 3.12%
Net Income
-11.2M
↓ 16.58%
Net Profit Margin
-176.3%
↑ 41.63%
Q2 FY24Q/Q Change
Revenue
5.6M
↓ 11.46%
Net Income
-13.3M
↑ 19.24%
Net Profit Margin
-237.43%
↓ 61.13%
FY11Y/Y Change
Total Assets
1.7M
↓ 28.29%
Total Liabilities
6.8M
↑ 36.12%
FY19Y/Y Change
Total Assets
31.7M
↑ 1805.47%
Total Liabilities
32.4M
↑ 374.15%
FY20Y/Y Change
Total Assets
70.0M
↑ 120.89%
Total Liabilities
45.2M
↑ 39.38%
FY21Y/Y Change
Total Assets
241.2M
↑ 244.54%
Total Liabilities
20.2M
↓ 55.31%
FY22Y/Y Change
Total Assets
190.7M
↓ 20.95%
Total Liabilities
26.5M
↑ 31.17%
FY23Y/Y Change
Total Assets
143.5M
↓ 24.76%
Total Liabilities
25.5M
↓ 3.84%
Q1 FY23Q/Q Change
Total Assets
190.7M
↓ 5.58%
Total Liabilities
26.5M
↑ 15.64%
Q2 FY23Q/Q Change
Total Assets
173.3M
↓ 9.11%
Total Liabilities
20.8M
↓ 21.31%
Q3 FY23Q/Q Change
Total Assets
160.9M
↓ 7.12%
Total Liabilities
21.3M
↑ 2.3%
Q4 FY23Q/Q Change
Total Assets
150.2M
↓ 6.7%
Total Liabilities
22.4M
↑ 4.97%
Q1 FY24Q/Q Change
Total Assets
143.5M
↓ 4.47%
Total Liabilities
25.5M
↑ 13.79%
Q2 FY24Q/Q Change
Total Assets
127.7M
↓ 10.96%
Total Liabilities
21.8M
↓ 14.43%
FY19Y/Y Change
Operating Cash Flow
-21.1M
-
Investing Cash Flow
-1.7M
-
Financing Cash Flow
14.9M
↑ 396.99%
FY20Y/Y Change
Operating Cash Flow
-31.0M
↑ 46.57%
Investing Cash Flow
-15.7M
↑ 824.48%
Financing Cash Flow
64.2M
↑ 331.97%
FY21Y/Y Change
Operating Cash Flow
-55.0M
↑ 77.33%
Investing Cash Flow
-13.3M
↓ 15.19%
Financing Cash Flow
216.7M
↑ 237.43%
FY22Y/Y Change
Operating Cash Flow
-58.5M
↑ 6.52%
Investing Cash Flow
-93.5M
↑ 603.36%
Financing Cash Flow
693.0K
↓ 99.68%
Q1 FY23Q/Q Change
Operating Cash Flow
-11.7M
↓ 22.84%
Investing Cash Flow
13.5M
↑ 5.23%
Financing Cash Flow
87.0K
↓ 42.38%
Q2 FY23Q/Q Change
Operating Cash Flow
-16.7M
↑ 43.17%
Investing Cash Flow
13.5M
↑ 0.0%
Financing Cash Flow
122.0K
↑ 40.23%

Technicals Summary

Sell

Neutral

Buy

Rapid Micro Biosystems Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Rapid Micro Biosystems Inc
Rapid Micro Biosystems Inc
-2.71%
-17.73%
-16.92%
-96.04%
-96.04%
Stryker Corporation
Stryker Corporation
0.86%
12.4%
15.49%
28.53%
77.74%
Boston Scientific Corp.
Boston Scientific Corp.
11.25%
36.51%
40.96%
76.8%
100.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.89%
34.72%
1.32%
-5.35%
56.97%
Abbott Laboratories
Abbott Laboratories
-3.84%
0.25%
-4.89%
-12.22%
35.01%
Medtronic Plc
Medtronic Plc
5.71%
8.68%
-4.84%
-33.51%
-4.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Rapid Micro Biosystems Inc
Rapid Micro Biosystems Inc
6.68
NA
0.0
-1.27
-0.4
-0.23
NA
2.48
Stryker Corporation
Stryker Corporation
37.6
37.6
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.33
63.33
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.77
38.77
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.15
32.15
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
26.83
26.83
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Rapid Micro Biosystems Inc
Rapid Micro Biosystems Inc
Buy
$35.6M
-96.04%
6.68
-224.73%
Stryker Corporation
Stryker Corporation
Buy
$125.6B
77.74%
37.6
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$110.8B
100.56%
63.33
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.4B
56.97%
38.77
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.5B
35.01%
32.15
13.96%
Medtronic Plc
Medtronic Plc
Buy
$112.2B
-4.04%
26.83
13.0%

Institutional Holdings

  • Bain Capital Life Sciences Investors, LLC

    19.68%
  • Kennedy Lewis Management LP

    11.53%
  • Glenview Capital Management LLC

    3.08%
  • ABG-WTT Global Life Science Capital Partners GP Ltd

    2.42%
  • BlackRock Inc

    2.38%
  • JPMorgan Chase & Co

    1.75%

Company Information

rapid micro biosystems provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology and personal care products. the company's growth direct(tm) system detects contamination earlier, delivering compelling economic benefits to manufacturers while improving their quality process. the growth direct(tm) system is the first and only automated system that accelerates testing while fitting with current regulatory practices and addressing all key applications.

Organization
Rapid Micro Biosystems Inc
Employees
193
CEO
Mr. Robert G. Spignesi Jr.
Industry
Healthcare

FAQs